𝗢𝗻𝗲 𝗯𝗿𝗮𝗻𝗱. 𝗘𝘅𝗽𝗼𝗻𝗲𝗻𝘁𝗶𝗮𝗹 𝗽𝗼𝘄𝗲𝗿 𝘁𝗼 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆. Earlier today, we announced our transition to MindWalk™ (NASDAQ: HYFT). The vision is now reality: one brand uniting technology, data and science to reshape discovery. MindWalk brings together IPA, BioStrand, and Talem Therapeutics under one identity: a customizable biointelligence ecosystem engineered to solve the complex. 𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝘀: • 𝗕𝗶𝗼-𝗻𝗮𝘁𝗶𝘃𝗲 𝗔𝗜 — LensAI™ powered by HYFT® technology, integrating 25B+ biologic connections to generate deeper insights, up to 3X faster • 𝗔 𝗼𝗻𝗲-𝗼𝗳-𝗮-𝗸𝗶𝗻𝗱 𝗱𝗮𝘁𝗮 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 — connecting sequence, structure, function, and literature to reveal hidden patterns • 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗹𝗮𝗯 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 — with a demonstrated track record of supporting 15+ programs to the clinic and achieving >98% discovery success in our leading B cell technology Patented. Validated. First-in-class. Together, we advance biologics discovery and development — providing deeper insight, greater scalability, and the potential for better patient outcomes. 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: 𝗺𝗶𝗻𝗱𝘄𝗮𝗹𝗸𝗔𝗜.𝗰𝗼𝗺 $IPA $HYFT #Biologics #IPA #BioStrand #Biotech #TechBio #DrugDiscovery #Antibodies

Press release: ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”. Today, IPA (ImmunoPrecise Antibodies), along with BioStrand and Talem, unify under a single identity: MindWalk. This evolution marks more than a name change. It reflects a strategic transformation into a Bio-Native AI company — built at the intersection of AI, multi-omics data, and advanced laboratory research. + New Nasdaq Ticker: HYFT + Unified Brand Identity: IPA, BioStrand, and Talem under one name — MindWalk + Business Model Shift: Transitioning from standalone wet-lab services to an integrated scalable platform company model, SaaS/DaaS offerings, and generative asset opportunities “Inspired by Darwin’s thinking path, MindWalk is about seeing what others can’t — patterns hidden in biology that point to better medicines,” said Dr. Jennifer Bath, CEO of MindWalk. “Our role is to convert that insight into impact, uniting science, computation, and responsible experimentation to change the pace of care.” At the core: LensAI™ powered by HYFT® technology — making biological diversity computable and accelerating discovery with clarity, speed, and depth. See full press release: ir.ipatherapeutics.com/news/… @BioStrandBV $IPA $HYFT #TechBio #Biologics #Antibodies #IPA #LensAI #DrugDiscovery

2024: A Year of Transformative Progress in Biotherapeutics This year, we harnessed the power of the LENSᵃⁱ platform powered by proprietary HYFT™ pattern recognition technology and advanced simulations to tackle the most complex challenges in drug discovery. By combining innovation, collaboration, and strategic growth, we achieved milestones that are reshaping the future of biotherapeutics. ✅ Precision Oncology Breakthroughs: Leveraging HYFT-powered simulations, we developed highly specific antibodies targeting the Tumor Microenvironment (TME), advancing oncology research. ✅ LENSᵃⁱ™ Evolution: Expanded access with four models—cloud, API integrations, service offerings, and partnerships—while launching new applications like Epitope Binning & Mapping and integrating optimized tools like AlphaFold2. ✅ Key Collaborations: Partnered with BioNTech (formerly Biotheus) to engineer therapies for hypoxic tumors and InterSystems to develop Vector Search, boosting efficiency and expanding AI-powered solutions. ✅ OncoResponse Success: Rabbit anti-LILRB2 antibodies, discovered through our rabbit B Cell Select platform, progressed to IND and Phase 1/2 trials, showing early positive clinical results in safety and efficacy. ✅ Industry Recognition: BioStrand stood out among over 1,000 applicants to win the 2024 InterSystems Impact Award, highlighting our innovative approach. ✅ Transformative Research: Collaborated with Mayo Clinic on neurodegenerative disease therapies, with findings published in Autophagy. ✅ Talem Advances: Made significant strides in TATX-112, targeting TrkB for aggressive cancers. ✅ Strategic Growth: Expanded Oss and Utrecht facilities, relocated headquarters to Austin, and hosted the first TECHday in Boston, featuring live demos of LENSᵃⁱ in action. ✅ Financial Excellence: Achieved record-breaking revenue for five consecutive quarters, capping off a landmark fiscal year. As we look to 2025, we remain committed to empowering clients with transformative solutions, seamless technology integration, and groundbreaking advancements in biotherapeutics. Together, we’re redefining what’s possible. $IPA #DrugDiscovery #Antibodies #AI

Catch Dr. Jennifer Bath's insightful Nasdaq interview with Jane King and Ari Zoldan, airing Saturday, September 28th! Dr. Bath explores how unlocking the full potential of integrated data and AI analytics is aimed at revolutionizing therapeutics research, enhancing patient outcomes, and driving greater efficacy while minimizing side effects. Don’t miss the segment airing: Date: Saturday, September 28th Location: KRON-TV in San Francisco Time: between 5:30-6:00 am PDT Watch the live stream on Roku, AppleTV, or Amazon Firestick by downloading the KRONon App. @QuantumMediaLLC @AriZoldan @MarketJane $IPA #QuantumMediaGroup #Nasdaq #TechBio #DataDriven #DrugDiscovery #mAb #Antibodies

Press Release: ImmunoPrecise Antibodies successfully engineers in silico antibodies to elusive tumor protein using its patented LENSᵃⁱ™ technology. "This marks a noteworthy milestone for the biotechnology industry, demonstrating LENSᵃⁱ's ability to engineer highly specific and validated antibodies for the exceedingly difficult environment around tumors, and doing so entirely on a computer,” said Dr. Jennifer Bath, IPA CEO. See the full release: ir.ipatherapeutics.com/news/… $IPA #ArtificialIntelligence #AI #Antibodies #mAb #DrugDiscovery #TechBio #BioTech

Tech update! Tune in to Jennifer Bath and Radius Research discussing the innovative LENSᵃⁱ™ Integrated Intelligence Platform API by BioStrand (IPA subsidiary). This game-changing API plugs directly into large pharma or biotech existing platforms, transforming their ability to harmonize data and unlock deep insights. A huge step forward for IPA in commercialization and development timelines, enabling direct access to LENSᵃⁱ for researchers in drug discovery. We are particularly focused on optimizing electronic health record (EHR) data to provide deep insights into precision medicine. Watch the full interview: youtu.be/ku3k52oRFzU?si=IAkt… $IPA #LENSai #BiotechAPI #PrecisionMedicine #Ai #LLM #EHR #Innovation #TechBio @RadiusResearch

ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer. Ms. Taylor is a seasoned financial executive with extensive experience in both early-stage and large growth companies, including those privately held, private equity-backed, and publicly listed. She has a strong background in driving growth, establishing infrastructure, and implementing effective strategies for value creation in dynamic, scaling environments. See full release: ipatherapeutics.com/news/imm… $IPA

IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Partnership to Develop First-In-Class AI Model for Pharmacogenomic Recommendations Using LENSᵃⁱ™ "With more genomic data and new pharmacogenetic insights, more advanced methods are urgently needed to analyze and predict treatment responses and adverse drug reactions. We believe that LENSᵃⁱ offers a potentially groundbreaking approach to creating an adaptive AI model that is designed to predict individual patient responses to both existing and new drugs." said Dr. Jennifer Bath, IPA President and CEO. See the full release highlighting the first integration of LENSᵃⁱ API: bit.ly/3zl7aJK $IPA @BioStrandBV #Pharmacogenomics #AI #ArtificialIntelligence #TechBio #Biotech #PersonalizedMedicine

BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery. The launch, led by Dr. Dirk Van Hyfte, highlights the integration of BioStrand's LENSᵃⁱ™, powered by their patented HYFT® technology, with a customizable Application Programming Interface (API). These new commercial capabilities will significantly enhance BioStrand’s ability to commercialize: 1.Partnerships with large companies which may include upfront payments, clinical milestones and commercial royalties. 2.Subscription services that enable a wide range of companies to access BioStrand’s unique capabilities using integration of the software into their existing platforms. Dirk Van Hyfte will showcase the new API-based offering in a live presentation today at 2 pm ET at the InterSystems Global Summit 2024. This year’s summit expects over 1,200 attendees from more than 28 countries. See Full Release: ir.ipatherapeutics.com/news/… @InterSystems $IPA #EHR #DrugDiscovery #AI #ArtificialIntelligence #mAb @BioStrandBV

IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR). BioStrand is leveraging their patented Foundation AI Model, LENSᵃⁱ™, by applying advanced Large Language Models (LLM) to capture real world data from Electronic Health Records (EHR). LENSᵃⁱ significantly enhances the analysis and integration of EHR data, enabling the integrated use of real-world data and evidence in drug discovery and the development of precision medicines. Dirk Van Hyfte MD, PhD, Head of Technology, IPA, to present live demonstration at the InterSystems Global Summit 2024 June 9-12, 2024 - National Harbor, Maryland See the full release: ir.ipatherapeutics.com/news/… @InterSystems $IPA #LLM #EHR #Ai #ArtificialIntelligence #LifeScience #FoundationAI #LLMS @BioStrandBV

ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSᵃⁱ™ Technology. The 2024 Impact Award, sponsored by @InterSystems , acknowledges BioStrand’s innovative LENSᵃⁱ technology, selected from over 1,000 client projects for its remarkable contributions. The selection committee, chaired by Professor Roberto Zicari, identified BioStrand’s work based on three key criteria: makes a significant difference, breaks new ground and sets an example. Tune in to today's Main Stage live to see the award presentation from 10:30-11:00am ET : linkedin.com/events/72038448… See the full release: ir.ipatherapeutics.com/news/… $IPA #GlobalSummit24 #TechBio #VectorSearch #DrugDiscovery #Biotech #ArtificialIntelligence #Antibodies #OmicsData @BioStrandBV

Discover how the collaboration between IPA subsidiary BioStrand and InterSystems is transforming technology and #drugdiscovery. Dirk Van Hyfte, BioStrand's Head of Innovation and Tom Dyar of InterSystems discuss the integration of BioStrand's LENSᵃⁱ Integrated Intelligence Technology with the InterSystems IRIS platform. This collaboration enhances vector search capabilities across various unstructured data types, optimizing efficiency and providing detailed insights at the subsequence level. A pivotal development in bridging technology with biotechnological advancements. See the full interview for a deeper exploration of these transformative developments: odbms.org/2024/05/on-using-v…‌ $IPA #VectorSearch #UnstructuredData #Biotech #TechBio #Innovation @BioStrandBV @InterSystems

BioStrand (an IPA subsidiary) and InterSystems announce they have entered a collaboration to combine technologies to integrate the new vector search capability of the InterSystems IRIS® data platform with BioStrand's LENSᵃⁱ™ platform, setting a new standard for AI-driven applications in healthcare and life sciences. Read the full release for details: ir.ipatherapeutics.com/news/… $IPA #Innovation #VectorSearch #DataModel #UniversalFoundationAiModel @InterSystems @BioStrandBV

IPA's subsidiary, BioStrand, and its advanced AI Integrated Intelligence platform, LENSᵃⁱ™, are now making their mark in the world with companies that provide database management systems. We're honored to receive recognition from InterSystems, an innovative data technology company. Dive into their latest blog to learn more about the latest advancements of the InterSystems IRIS data platform and Vector Search Embeddings, along with their promising possibilities with generative AI-based applications. See the full blog to learn more: intersystems.com/news/iris-v… $IPA #Innovation #AI #ArtificialIntelligence #LLM #VectorEmbedding #DrugDiscovery #Biotechnology #TechBio

Big week at the highly anticipated NVIDIA conference, where Team IPA - comprising Dr. Jennifer Bath, IPA CEO, Dr. Dirk Van Hyfte, BioStrand Head of Innovation, and Frederic Chabot, IPA Head of Corporate Development - look forward to meeting to share the latest breakthrough advancements of the LENSᵃⁱ™ Universal Foundation AI model. Join the conversation on how this innovation empowers large pharma to gain a research competitive edge in antibody discovery and enables healthcare giants to streamline and integrate complex data management. Don't miss out on the future of healthcare innovation! $IPA $NVDA #NVIDIA #TechBio #Biotech #FoundationAIModel #ArtificialIntelligence #DrugDiscovery #Antibodies #HealthcareInnovation

IPA’s subsidiary BioStrand Secures Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT® Technology Dirk Van Hyfte MD, PhD, Co-Founder and Head of Innovation of BioStrand will be presenting its findings live at HIMSS24 conference in Orlando, Florida Don't miss the insightful presentation at the Innovator Showcase, hosted by our tech partner InterSystems, where our subsidiary, BioStrand, will take the spotlight. On March 13th, Dirk Van Hyfte, will showcase our next-gen Universal Foundation AI Model for Multiscale Biological Data Integration. Explore the significance of data optimization and how we utilize embedded HYFT and LLM technologies to enrich data integration, revealing deeper more meaningful insights in life sciences. Join us! Innovator Showcase Presentation Date & Time: Wednesday, March 13 | 12:15 pm ET Location: Booth 1361 | Hall A - Orlando, FL Visit InterSystems' booth, #1361, to see our innovation in action. We look forward to connecting with you at #HIMSS24! See full press release: ipatherapeutics.com/news/ipa… $IPA #DataIntegration #HIMSS2024 #LLM #TechBio #DrugDiscovery #Antibodies #Innovation #AI #ArtificialIntelligence @BioStrandBV

New tech ALERT: BioStrands' Epitope Binning Redefines Early Lead Selection in Drug Discovery Introducing our latest addition to the LENSᵃⁱ™ BioIntelligence Suite: Epitope Binning! Now researchers can conduct fast, high-throughput assessments for more informed early triaging of lead candidate pools. Our proven technology matches wet lab binning methods with precision and accuracy, requiring only protein sequences—no need for physical material production. This breakthrough empowers efficient and effective drug discovery. Learn more: biostrand.ai/lens-ai-epitope… #EpitopeBinning #AI #ArtificialIntelligence #InSilico #DrugDiscovery #Antibodies #Innovation #TechBio #Biotherapeutics

Highlights from JPM Healthcare 2024 🧬 It's the "Year of the Antibody" at JPM Healthcare 2024, and we're buzzing with excitement! Dr. Jennifer Bath, CEO of IPA, participated as a panelist in the sold-out discussion titled "Connecting Clusters of Excellence: Europe as Your Gateway to Global Success". Key takeaways: • Leveraging local innovation hubs effectively to create expansive global networks. • Building teams strategically with diverse experts to fuel innovation. • Belgium's favorable tax and IP policies position it as a strategic hub for life sciences. Insightful hands-on contributions from biotech leaders and consultants enriched the discussion. Thank you, Health Campus Limburg DC, for organizing this impactful event! Stay connected for more updates from JPM and the forefront of healthcare innovation! Let's start the conversation on leveraging global hubs. bit.ly/46XqDLE $IPA #JPMHealthcare #JPM24 #Innovation #LifeSciences #GlobalNetworks #AI #ArtificialIntelligence #Antibodies #Biotechnology #HealthCampusLimburgDC

Ipa is thrilled to announce that its subsidiary, @BioStrandBV, has published a preprint of its groundbreaking white paper titled, "New Paradigm for Biological Sequence Retrieval Inspired by Natural Language Processing and Database Research" on biorxiv bit.ly/3QvODiC‌‌. The publication delves into the intricacies of BioStrand’s patented HYFT-based methodology, a novel and proprietary approach to biological sequence retrieval, and it’s clear comparative advantages over the gold standard algorithm, Basic Local Alignment Search Tool “BLAST”. See full press release: bit.ly/47dcg6I #HYFTs #AI #ArtificialIntelligence #AI #Innovation #DrugDiscovery #NLP #Antibodies #AntibodyDiscovery @biorxivpreprint

Latest significant technology advancement: IPA announces that its subsidiary, BioStrand, has launched its state-of-the-art Retrieval Augmented Generation (RAG)-based Large Language Model (LLM) platform. Dirk Van Hyfte, MD, PhD, Co-Founder and Head of Innovation of BioStrand commented "This integration, viewed through the prism of our patented HYFTs, not only simplifies complex information but opens a new dimension of predictive analysis. It notably enhances the platform's ability to delineate the structure, function, and potential applications of large molecules, representing a meaningful step towards more intuitive and insightful data analysis in the life sciences sector." See full release: ir.ipatherapeutics.com/news/… $IPA #AI #ArtificialIntelligence #Innovation #DrugDiscovery #Antibodies #LLM #Biologics #Biotechnology #TechBio